RxDoctor Payments Data

Roger Wood, MD

Hematology & Oncology · Dayton, OHNPI 1972563211

Payments from drug & device makers

$12,677in general payments, 2019–2025

Across 621 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$891
  • Novartis$881
  • Merck$807
  • Johnson & Johnson$701
  • AbbVie$609
  • Daiichi Sankyo Inc.$511
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,08095%
  • Education$5975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)41$891
Novartis51$881
Merck36$807
Johnson & Johnson32$701
AbbVie29$609
Daiichi Sankyo Inc.27$511
Incyte Corporation24$503
E.r. Squibb & Sons, L.L.C.29$502
Gilead(2 entities)22$441
Exelixis Inc.3$414
Bayer22$396
Pfizer23$381
Pharmacyclics LLC, An Abbvie Company17$352
Bristol Myers Squibb15$314
Lilly USA, LLC17$293
Sanofi13$255
Tersera Therapeutics LLC10$252
Genentech USA, Inc.12$228
Amgen15$225
Regeneron Healthcare Solutions, Inc.12$222
Ipsen Biopharmaceuticals, Inc8$219
Eisai Inc.11$204
Sobi, Inc6$187
GSK9$173
Jazz Pharmaceuticals Inc.6$171
Stemline Therapeutics Inc.8$163
Astellas Pharma US Inc8$156
Array Biopharma Inc8$153
Takeda Pharmaceuticals U.S.A., Inc.7$145
Taiho Oncology, Inc.6$115
Genmab U.S., Inc.4$111
Geron Corporation4$100
Seagen Inc.6$98
Blueprint Medicines Corporation5$93
Karyopharm Therapeutics Inc.5$78
ADC Therapeutics America, Inc.4$73
Beone Medicines USA, Inc.2$70
Kyowa Kirin, Inc.4$68
Deciphera Pharmaceuticals Inc.4$64
Beigene USA, Inc.4$63
Adaptive Biotechnologies Corporation3$63
AVEO Pharmaceuticals, Inc.3$62
Legend Biotech USA Inc.3$55
Tempus AI, Inc2$54
Servier Pharmaceuticals LLC3$53
Rigel Pharmaceuticals, Inc.3$48
Cumberland Pharmaceuticals, Inc.2$44
Secura Bio, Inc.3$44
Apellis Pharmaceuticals, Inc.2$40
Pharmaessentia USA Corporation2$40
Agios Pharmaceuticals, Inc.2$39
Caris MPI, Inc.2$38
Foundation Medicine, Inc.2$38
Pharmacosmos Therapeutics Inc.2$37
Springworks Therapeutics, Inc.1$36
EMD Serono, Inc.2$35
Puma Biotechnology, Inc.2$31
Alnylam Pharmaceuticals Inc.2$30
Progenics Pharmaceuticals, Inc.1$25
Morphosys, US Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,677 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$2,757,924
Medicare patients
576
Services billed
112,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide45$770,625
Lenalidomide34$502,466
XtandiEnzalutamide24$342,622
CalquenceAcalabrutinib Maleate19$260,935
VerzenioAbemaciclib11$165,390
EliquisApixaban130$100,031
Abiraterone Acetate44$46,025
OrgovyxRelugolix13$35,611
XareltoRivaroxaban13$9,271
Cyclosporine11$7,913
Anastrozole196$2,453
Ondansetron OdtOndansetron73$2,320
Imatinib Mesylate13$2,037
Tamoxifen Citrate30$1,498
Dexamethasone72$1,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$314$770,62545 claims
Astellas Pharma US IncXtandi$156$342,62224 claims
AstraZenecaCalquence$891$260,93519 claims
Lilly USA, LLCVerzenio, Olanzapine$293$166,05655 claims
PfizerEliquis$381$100,031130 claims
Johnson & JohnsonXarelto$701$9,27113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →